|
|
Last Modified: 1/29/2008  First Published: 12/8/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV, Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
21 and under
|
|
|
|
Other
|
|
|
|
GPOH-NB2004 EU-20661, NCT00410631
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Approved-not yet active
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
BO21015 2008-000662-23, NCT00700180
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 to 75
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
XYL014 NCT00708812
|
|
|
|
|
|
|
|
Last Modified: 3/30/2007  First Published: 9/1/2002 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 to 65
|
|
|
|
Other
|
|
|
|
LMU-DOLPHIN-1 EU-20220, NCT00045461
|
|
|
|
|
|
|
|
Last Modified: 5/22/2007  First Published: 12/23/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
Adult
|
|
|
|
Other
|
|
|
|
RCOG-MRC-CHORUS EU-20350, ISRCTN74802813, NCT00075712
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 to 75
|
|
|
|
Other
|
|
|
|
Haema CBF SCLC UK/AS 01 NCT00168896
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 to 59
|
|
|
|
Other
|
|
|
|
N06IAA NCT00448266
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
OXC4T4-302 NCT00507429
|
|
|
|
|
|
|
|
Last Modified: 6/9/2008  First Published: 9/26/2007 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
4 and over
|
|
|
|
NCI
|
|
|
|
RPCI-I-72806 I 72806, NCT00536601
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
Not specified
|
|
|
|
Other
|
|
|
|
2006-0374 NCT00539500
|
|
|
|